Life Biosciences Announces First-in-Human Data from Ongoing Phase 1 Trial Evaluating ER-100 in Optic Neuropathies
The company reported early safety observations and visual-field changes in a three-person Phase 1 cohort; the trial is ongoing and the findings are preliminary.
TL;DR
- Life Biosciences reported first-in-human observations from its ongoing ER-100 Phase 1 study in optic neuropathies.
- The company said three participants had completed eight weeks of follow-up and two showed improvement in some visual-field measures.
- The small, early cohort does not establish efficacy, and longer follow-up and additional participants are still needed.
Life Biosciences announced initial human data from its ongoing Phase 1 study of ER-100, an investigational therapy for optic neuropathies including open-angle glaucoma. STAT and TIME also reported on the company’s October 8 presentation. [1][2][3] [1] [2] [3]
The company said three participants had completed eight weeks of follow-up and that the treatment was tolerated during that period. STAT described the update as an early safety readout; TIME reported that two participants showed changes in portions of their visual fields. [1][2][3] [1] [2] [3]
ER-100 is being tested in a Phase 1 trial, whose primary purpose is to assess safety and tolerability. The reports describe a very small initial group and preliminary observations, not a controlled demonstration that the therapy improves vision. [1][2][3] [1] [2] [3]
The study remains ongoing, and the cited coverage does not provide a full peer-reviewed dataset or establish how durable the reported changes may be. Safety over longer follow-up, results in a larger group, and whether later studies confirm a clinical benefit remain open. [1][2] [1] [2]
Why it matters
The update is an early clinical milestone for partial epigenetic reprogramming in people, but the size and stage of the study sharply limit what can be concluded about benefit.
Editor's note
TODO-review: Verify the detailed visual-field endpoints against the conference presentation before expanding this summary. Company-reported preliminary data; no efficacy conclusion.